On October 24, 2025, Eli Lilly's $5 billion investment in a new Virginia manufacturing facility was highlighted, marking the first of four planned U.S. sites. This expansion aims to make the company largely tariff-proof by enabling 100% domestic production for American patients, directly responding to President Trump's aggressive tariffs on foreign-made goods[1]. The news underscores Eli Lilly's strategy to protect its bottom line and maintain strong revenue growth, supported by its fast-growing drug portfolio. LLY stock closed at $821.04 (+1.06%) on October 23, 2025 and is trading at $822.12 (+0.13%) pre-market, reflecting positive sentiment but no outsized price reaction to the announcement.